about
Practice-based evidence: profiling the safety of cilostazol by text-mining of clinical notesSilencing of int6 gene restores function of the ischaemic hindlimb in a rat model of peripheral arterial disease.Potential emerging therapeutic strategies to prevent restenosis in the peripheral vasculature.Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication.Multidisciplinary approach to the diagnosis and management of patients with peripheral arterial disease.Current endovascular treatment of peripheral arterial disease.Future innovations in anti-platelet therapies.Management of peripheral arterial disease in the elderly: focus on cilostazolTargeting cancer with phosphodiesterase inhibitors.Peripheral artery disease. Part 2: medical and endovascular treatment.Diagnosis and treatment of peripheral arterial disease in CKD patients.Current therapies and investigational drugs for peripheral arterial disease.Pharmacodynamic interaction studies of Ginkgo biloba with cilostazol and clopidogrel in healthy human subjects.A Validated HPLC/MS Limit Test Method for a Potential Genotoxic Impurity in Cilostazol and its Quantification in the API and in the Commercially Available Drug Product.Successful sequential drug eluting balloon angioplasty to chronic total occluded popliteal artery in a patient with thromboangitis obliterans by PCR.Effects of cilostazol on resting ankle pressures and exercise-induced ischemia in patients with intermittent claudication.The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease.
P2860
Q28533275-8A172CCC-10EB-4518-88FC-BF7F0C895893Q33965740-DA5B25D7-5FBE-4FD0-8B9E-C5043689C2EFQ34733613-6CA71DA9-F25E-4C36-B0F7-FCE294782876Q35015642-127106F0-5AC8-4714-9FBB-789F5BAC8210Q35857344-B1C9EB13-175B-4431-99B2-36757270897DQ36753255-6750A83B-915E-4A35-AF39-F45407FC4043Q36753593-BE7DD495-1AC9-41AC-B4A4-197CD368CEDAQ36892864-A6644127-C55A-4C31-BC7A-327803FFB660Q37650389-FEC8D712-76DD-4818-8E5F-F357E93F5DDFQ37889106-DEA1090E-20C4-4847-9CBC-4D0CB71364EAQ38052160-D211A84B-614A-4071-ACF5-1364D55140BDQ38657444-3F9F82E7-2304-4E80-B4A3-41380FD5D736Q41123941-CBFE768E-349F-47E5-8228-DB0F6860E7A4Q41771250-63997130-C557-49DA-A36F-AD56CEA3A47AQ41869103-B52E4DC0-2874-430A-84C3-A49AE5C281C7Q43853764-339D940C-F7F0-4A70-A0DE-26C2439A2850Q46363779-CFD1D77F-2BDC-48C4-8415-B7A183A09ACF
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Cilostazol: treatment of intermittent claudication.
@ast
Cilostazol: treatment of intermittent claudication.
@en
type
label
Cilostazol: treatment of intermittent claudication.
@ast
Cilostazol: treatment of intermittent claudication.
@en
prefLabel
Cilostazol: treatment of intermittent claudication.
@ast
Cilostazol: treatment of intermittent claudication.
@en
P2860
P356
P1476
Cilostazol: treatment of intermittent claudication.
@en
P2093
E R Mohler
M P Reilly
P2860
P356
10.1345/APH.19408
P407
P577
2001-01-01T00:00:00Z